Weekly Recap: Zymeworks Inc. raises 2026 guidance and secures $350M lien
Zymeworks Inc. (NASDAQ:ZYME) lifted 2026 guidance after acquiring Theravance and FDA approval of Ziihera, targeting $278—$292M revenue and $114—$128M adjusted EBITDA while securing $350M senior notes with a first—priority lien and bolstering tech and IP with new hires.Previous Week RecapThis is an…